Arcadia Biosciences Inc. Common Stock (RKDA)

FairStock Score: 56/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for durable competitive advantages, honest earnings, and a margin of safety. Arcadia fails most of those tests. In fiscal 2025, the year ended 2025-12-31, revenue was $4.9M and net loss was $2.3M, or diluted EPS -$1.71. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $1.4M and net loss was $6.3M, or -$2.09 per diluted share - so the latest quarter's loss was nearly three times the full prior year's loss. A FairStock profit-growth figure of 67.13% sounds hopeful, but it reflects a narrower loss: FY2025 net loss $2.3M versus FY2024 net loss $7.0M, not real profit. The Lynch category is none because the company lost money in each of the last four years. Free cash flow is negative $2.5M on a trailing basis, and the FairStock FCF yield is -506.1%. The Piotroski score is 3/9 and the Altman Z-score is -68.48, both consistent with financial fragility. At the $0.21 close on 2026-10-13, the FairStock P/B is 0.72 and market cap is $501,116, while ROE is -430.93% and ROCE is -34.76%. A price below book can be a bargain, but not when capital is being destroyed and cash is burning. Revenue is small and the company has only eight employees; its 52-week range of $0.19 to $5.63 shows extreme volatility. There is no visible moat in plant-based foods; Zola and GoodWheat are small brands fighting larger competitors. This is not a Graham margin of safety - it is a speculative nano-cap whose cheapness depends on a sharp turnaround that has not yet appeared.

In plain English: Arcadia Biosciences makes plant-based food and drink brands such as GoodWheat and Zola coconut water. The business is tiny and unprofitable: in fiscal 2025, the year ended 2025-12-31, it had $4.9 million of revenue and a $2.3 million net loss, and in fiscal Q2 2026, the quarter ended 2026-06-30, the net loss was $6.3 million. The stock price is very low and trades below its accounting book value, but the continuing losses and cash burn make the cheapness questionable.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer